Decreased cardiac mortality with nicorandil in patients with ischemic heart failure

Table 2 Subgroup analysis for cardiac mortality: Nicorandil use

Factor	Subgroup	n	HR	95% Cl	P value	Interaction P value
Total		334	0.512	0.275–0.953	0.035	-
Age	≥75	143	0.807	0.344–1.890	0.621	0.252
Age	<75	191	0.380	0.153–0.942	0.037	0.252
Sex	Male	255	0.449	0.216–0.932	0.032	0.403
Sex	Female	79	0.737	0.213–2.547	0.629	0.403
LVEF	Reduced	244	0.623	0.325–1.192	0.153	0.405
LVEF	Preserved	90	0.245	0.029–2.102	0.200	0.405
LMT	Present	19	1.240	0.000–3.420	0.581	0.968
LMT	Absent	315	0.492	0.259–0.934	0.030	0.968
3VD	Present	85	0.672	0.244–1.849	0.441	0.482
3VD	Absent	249	0.425	0.188–0.962	0.040	0.482
PCI	Present	245	0.556	0.272–1.138	0.108	0.646
PCI	Absent	89	0.422	0.120–1.483	0.179	0.646
CABG	Present	69	0.181	0.036–0.897	0.036	0.128
CABG	Absent	265	0.718	0.366–1.409	0.336	0.128
Diabetes	Present	207	0.412	0.177–0.957	0.039	0.361
Diabetes	Absent	127	0.742	0.296–1.858	0.523	0.361
CKD	Present	229	0.434	0.217–0.871	0.019	0.206
CKD	Absent	105	1.252	0.280–5.596	0.769	0.206
Dialysis	Present	44	0.338	0.073–1.568	0.166	0.595
Dialysis	Absent	290	0.557	0.282–1.100	0.092	0.595
β-blockers	Present	278	0.483	0.229–1.022	0.057	0.469
β-blockers	Absent	56	0.830	0.273–2.523	0.743	0.469
Statins	Present	220	0.720	0.324–1.604	0.422	0.425
Statins	Absent	114	0.400	0.139–1.153	0.090	0.425
Anti-platelet agents	Present	299	0.600	0.316–1.140	0.119	0.907
Anti-platelet agents	Absent	35	0.041	0.000–215.058	0.464	0.907
Nitrates	Present	78	0.551	0.188–1.616	0.277	0.814
Nitrates	Absent	256	0.474	0.219–1.027	0.058	0.814

LVEF left ventricular ejection fraction, LMT left main trunk, 3VD three-vessel disease, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, CKD chronic kidney disease

ISSN: 1471-2261